MariTide

News

Amgen's big reveal of obesity data falls a little flat

Top-line phase 2 results with Amgen's MariTide drug for obesity are finally in, but don't seem to have lived up to investor expectations

News

Amgen plays down safety concern with obesity candidate

Amgen has rebuffed claims made by an analyst suggesting that its obesity drug MariTide is associated with reductions in bone mineral density that could undermine its ability to compete in t

Patients

pharmaphorum podcast Episode 256, Dean Erhardt, D2 Solutions

Providing patient access to new therapies, with Dean Erhardt

Dean Erhardt, founder of D2 Solutions, discusses patient access today versus the state of patient access tomorrow.

/themes/custom/pharmaphorum_theme/library/img/article-label-image/ondemand.png

Sales & Marketing

Using AI-driven synthetic personas to take your insights fur...

As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.

Editor's Picks